Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zugasti Ines, Lopez-Guerra Monica, Castaño-Díez Sandra, Esteban Daniel, Avendaño Alejandro, Pomares Helena, Perez Ana, García-Ávila Sara, Conejo Irene Padilla, de la Fuente Montes Cristina, Martínez-Roca Alexandra, Merchán Beatriz, Jiménez-Vicente Carlos, Guijarro Francesca, Álamo Jose Ramón, Cortes-Bullich Albert, Torrecillas Victor, Mont Lucia, Carcelero Esther, Riu Gisela, Zamora Lurdes, Bargay Joan, Triguero Ana, Suarez-Lledó Maria, Salas Maria Queralt, López-Cadenas Felix, Ramos Fernando, Xicoy Blanca, Valcárcel David, Arnan Montserrat, Martínez Carmen, Rovira Montserrat, Fernández-Avilés Francesc, Díez-Campelo Maria, Esteve Jordi, Díaz-Beyá Marina
Аннотация
METHODS: We retrospectively evaluated HMA/VEN as a bridge to allo-SCT in 30 patients with HR-MDS or CMML eligible for transplant. Eighteen patients were treatment-naïve and 12 were refractory or relapsed (R/R).
RESULTS: As defined by the IWG 2023 criteria, the overall response rate (ORR) was 90% and the composite complete response rate was 77%. For the R/R patients, ORR was 83%. The allo-SCT rate was 83%, and the allo-SCT rate of those patients treated exclusively with HMA/VEN without further bridge therapies was 76%. One- and two-year post-allo-SCT survival was 75% and two-year cumulative incidence of relapse was 30.5%. Follow-up of measurable residual disease identified some molecular relapses that were controlled with preemptive treatment.
CONCLUSIONS: Our findings indicate that HMA/VEN combination therapy shows promise as a bridging strategy to allo-SCT in HR-MDS and CMML.